This educational activity is jointly provided by AXIS Medical Education and the Association of Community Cancer Centers (ACCC).
This activity is supported in part by educational grants from Astellas and Seattle Genetics, Celgene Corporation, Daiichi Sankyo, Inc., Exelixis, Inc., Pfizer, Inc., TESARO, Inc. and educational funding by Amgen.
Multidisciplinary clinical cancer care team members including—but not limited to—medical, surgical, and radiation oncologists; fellows; gastroenterologists; nephrologists; neurologists; pathologists; pulmonologists; radiologists; researchers; oncology nurse practitioners and oncology nurses; pharmacists; physician assistants; and other allied health care professionals.
Overview: ASCO DIRECT™ HIGHLIGHTS MEETINGS condense the most cutting-edge science and education from the world’s premier oncology event, the ASCO Annual Meeting, into a one-day program. The abstracts chosen for presentation and discussion reflect state-of-the-art developments and recent advances in oncology that will directly impact patient care. The program features in-depth discussion and analysis on the latest scientific findings in primary disease sites and practice-changing advances in cancer treatment. Expert faculty will place abstract findings into clinical context and discuss how the results may change the current standard of care.
At the end of this educational activity, participants should be able to:
6:30 – 7:30 AM Registration and Networking Breakfast
7:30 – 7:40 AM Introduction and Pre-Activity Assessment
7:40 – 8:10 AM Leukemia/Lymphoma Richard R. Furman, MD
8:10 – 8:40 AM Healthcare Delivery and Survivorship Carrie Tompkins Stricker, PhD, RN, AOCN®
8:40 – 9:40 AM Hepatobiliary/Pancreatic/Gastrointestinal Cancers Rachna Shroff, MD, MS
9:40 – 10:05 AM Networking Break
10:05 – 10:35 AM Melanoma and Skin Cancers Michael Postow, MD
10:35 – 11:05 AM Gynecologic Cancers Premal Thaker, MD, MS
11:05 – 11:40 AM Genitourinary Cancers Evan Y. Yu, MD
11:40 AM – 12:25 PM Networking Lunch
12:25 – 12:55 PM Breast Cancer Joseph A. Sparano, MD
12:55 – 1:25 PM Multiple Myeloma Sundar Jagannath, MD, FACP
1:25 – 1:55 PM CAR T-cell Therapies Krishna Komanduri, MD
1:55 – 2:25 PM Quality Management and Care Improvement Keith D. Eaton, MD, PhD
2:25 – 2:45 PM Networking Break
2:45 – 3:15 PM Cancer Genomics and Molecular Diagnostics Jeffrey Gregg, MD
3:15 – 3:45 PM Lung Cancer Jamie Chaft, MD
3:45 – 4:00 PM Program Evaluation/Q&A
In support of improving patient care, this activity has been planned and implemented by AXIS Medical Education and Association of Community Cancer Centers (ACCC). AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 7.0 Interprofessional Continuing Education (IPCE) credit for learning and change.
Credit Designation for Physicians
AXIS Medical Education designates this live activity for a maximum of 7.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Maintenance of Certification: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 7 MOC point(s) in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC point(s) equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.
Credit Designation for Pharmacists
This application-based activity is approved for 7.0 contact hours of continuing pharmacy education credit JA4008106-9999-19-026-L01-P.
Credit Designation for Nursing
AXIS Medical Education designates this continuing nursing education activity for 7.0 contact hours.
Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.
AXIS Contact Information
For information about the accreditation of this program please contact AXIS at firstname.lastname@example.org.
AXIS Medical Education requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:
Name of Faculty or Presenter/Planner
Reported Financial Relationship
Richard R. Furman, MD
Richard R. Furman, MD reported a financial interest/relationship or affiliation in the form of Consultant: AbbVie Inc.; Acerta Pharma; AstraZeneca Pharmaceuticals LP; BeiGene; Genentech, Inc.; Janssen Oncology; Loxo Oncology, Inc.; OncoTracker, Inc.; Pharmacyclics; Sunesis Pharmaceuticals, Inc.; TG Therapeutics, Inc.; Verastem Oncology. Serve(d) as a speaker or a member of a speakers bureau for: Janssen Oncology. Research grant: Acerta Pharma; TG Therapeutics. Data and Safety Monitoring Board: Incyte Corporation.
Carrie Tompkins Stricker, PhD, RN, AO
Carrie Tompkins Stricker, PhD, RN, AOCN reported a financial interest/relationship or affiliation in the form of Officer: Carevive Systems, Inc. Serve(d) as an employee for a commercial interest entity: Carevive Systems, Inc. Have a 5% or greater equity interest in: Carevive Systems, Inc. Received income in any amount from: Carevive Systems, Inc. Ownership interest: Carevive Systems, Inc.
Rachna Shroff, MD, MS
Rachna Shroff, MD, MS reported no financial interest/relationships.
Michael Postow, MD
Michael A. Postow, MD reported a financial interest/relationship or affiliation in the form of Consultant: Bristol-Myers Squibb Co.; Merck & Co., Inc.; Novartis Pharmaceuticals Corp.; Array BioPharma. Serve(d) as a speaker or a member of a speakers bureau for: Bristol-Myers Squibb, Co. Contracted research: Bristol-Myers Squibb Co.; Merck & Co., Inc.; Array BioPharma; Rgenix; Novartis Pharmaceuticals Corp.; Infinity Pharmaceuticals; AstraZeneca Pharmaceuticals LP.
Premal Thaker, MD, MS
Premal Thaker, MD, MS reported a financial interest/relationship or affiliation in the form of Consultant: Celsion; Tesaro; Iovance Biotherapeutics, Inc.; Stryker; Unleash Immuno Oncolytics; Oncolytics Biotech, Inc.; ImmunoGen, Inc.; Genelux. Serve(d) as a speaker or a member of a speakers bureau for: Merck; AstraZeneca; Tesaro. Research grant: Merck & Co., Inc.; Tesaro. Ownership interest: Celsion.
Evan Y. Yu, MD
Evan Y. Yu, M.D. reported a financial interest/relationship or affiliation in the form of Consultant: QED Therapeutics; Amgen; Seattle Genetics; Bayer Pharmaceuticals Corp; Pharmacyclics; Janssen Oncology; Merck & Co, Inc.; Dendreon. Research grants and Contracted Research: Dendreon; Seattle Genetics; Merck & Co, Inc.; Bayer Pharmaceuticals Corp.
Joseph A. Sparano, MD
Joseph A. Sparano, MD reported a financial interest/relationship or affiliation in the form of Research grants: Deciphera Pharmaceuticals, Inc.; Prescient Therapeutics. Received income in any amount from: Daiichi Sankyo; CStone Pharmaceuticals; Pfizer, Inc.; Cardinal Health; Roche. Contracted Research: Radius Health; Roche. Ownership interest: MetaStat Inc.
Sundar Jagannath, MD, FACP
Sundar Jagannath, M.D. FACP reported a financial interest/relationship or affiliation in the form of Consultant: Celgene Corporation; Janssen Oncology; Karyopharm Therapeutics; Bristol-Myers Squibb Co.; Merck & Co., Inc.; Abbvie, Inc.
Krishna Komanduri, MD
Krishna Komanduri, MD reported a financial interest/relationship or affiliation in the form of Consultant: Kite Pharma/Gilead Sciences, Inc.; Novartis Pharmaceuticals Corp.; Celgene Corporation; Kiadis Pharma; Atara Biotherapeutics; Helocyte; Autolus Therapeutics. Contracted research: Kite Pharma/Gilead Sciences, Inc.; Atara Biotherapeutics; Autolus Therapeutics; Kiadis Pharma.
Keith D. Eaton, MD, PhD
Keith D. Eaton, MD, PhD reported a financial interest/relationship or affiliation in the form of Research grant: Mirati Pharma
Jeffrey Gregg, MD
Jeffrey Gregg, MD reported a financial interest/relationship or affiliation in the form of Consultant: Foundation Medicine, Inc. Serve(d) as a speaker or a member of a speakers bureau for: Bristol-Myers Squibb Co; AstraZeneca Pharmaceuticals LP; Novartis Pharmaceuticals Corp. Research grant: AstraZeneca Pharmaceuticals LP.
Jamie Chaft, MD
Jamie E. Chaft, MD, reported a financial interest/relationship or affiliation in the form of Consultant: AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company. Research grant to the institution: Bristol-Myers Squibb Company; Merck & Co., Inc.; Genentech, Inc.; AstraZeneca Pharmaceuticals LP.
The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:
Name of Planner/Manager/Reviewer
Keola Beale, MD
Nothing to disclose
Chuck Miller, MD
Emily Touloukian, DO
Asutosh “Bobby” Gor, MD
Jennie Crews, MD, MMM, FACP
Ali McBride, PharmD, MS, BCOP
Advisor: Bristol-Myers Squibb
John Allan, MD
Advisor/Consultant: Abbvie, Genentech, Pharmacyclics, Sunesis, Verastem, Bayer, Janssen, AstraZeneca
Stuart P. Feldman, MD
Gene Saylors, MD
Leigh Boehmer, PharmD, BCOP
Robert Mocharnuk, MD
Common stock: Merck
Marilyn Haas, PhD, RN, CNS, ANP-BC
Dee Morgillo, MEd.,CHCP
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be emailed to you within 3 weeks. For pharmacists, your record will be uploaded to CPE Monitor.